Bluechiip Ltd Mar 2017

Transcription

1 Bluechiip Ltd Mar 2017 Unique patented MEMS technology combining secure wireless tracking with integrated temperature sensing for extreme environments

2 Introduction Bluechiip Sample Tracking Disclaimer Material used in this presentation is a summary of available information, and while given in good faith, is professional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering investment in the company. Certain information may have been derived from third parties and though BCT has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by BCT. Any forward-looking statements in this presentation involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT. Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guarantee in relation to this presentation. BCT reserves right to update, amend or supplement information in this presentation at any time in its absolute discretion without incurring any obligation to do so. 2

3 Introduction Corporate Our Team Board Iain Kirkwood Andrew McLellan Michael Ohanessian Chairman Managing Director Non-executive Director Experienced investor and nonexecutive director (listed and unlisted). Iain has considerable practical and operational experience gained from a successful financial career spanning 35 years including in resources, manufacturing and latterly healthcare in Australia, Britain and the USA. Iain has been a major shareholder in Bluechiip for over 5 years. Experienced in innovation and commercialisation combined with significant technical and operational background. Andrew has held senior positions including as VP of Business Development in North America and Director at Leica Microsystems (previously Vision BioSystems a division of the publicly listed Vision Systems), and as CEO of the Advanced Manufacturing Co-operative Research Centre (AMCRC) CEO and Managing Director of Praemium Ltd, Michael brings executive experience in technology-related businesses. Previously CEO of Vision BioSystems Michael led the technology commercialisation into global markets before its parent Vision Systems was acquired by US based Danaher Corp. Michael brings a mixture of operational, strategic and leadership capabilities to his role at Bluechiip. Team Scott Turner Dr Ian Johnston Irvin Teoh Oscar Val David White & Hugh Douglas Engineering Manager Product Engineering Manager, MEMS (EU) Finance Manager Technical Sales and Marketing Manager Business Development North America (US) 4

4 Share Price (cent) Volume (million) Introduction Corporate Corporate overview Top Shareholders Share Price Pulitano Family 8.82% Dr. Stephen Woodford 8.37% 8c 7c 6c Chairman & Entities 7.32% 5c 4c 10 8 Planet Innovation 5.02% 3c 2c 6 4 Top 20 Shareholders 51.48% Founder 1.57% 1c 0c 2 0 Summary (As at 31 Jan 2017) Number of Shareholders 708 Shares on Issue 271,810,092 Share Price 4.0c Market Cap. $10.87m Cash Balance (31 Dec 2016) $1.092m 4

5 Introduction Overview Bluechiip Sample tracking for extreme environments using MEMS sensors Our Product : Chip + Reader + Software Unique Micro-Electro Mechanical Systems (MEMS) micro device, superior to labels, barcodes and RFID Provides ID extremely difficult to copy Operates reliably between -196ᵒC & 100ᵒC Instant sample temperature sensing Reads in under 0.3 second, even through frost Sterilisation resistant including Gamma radiation Can be moulded into any plastic Reduces human error Increases productivity 5

6 Biobanking Today Our Solution Alternative technologies Gamma Resistant HUMAN READABLE BARCODES RFID BLUECHIIP Cryo safe Survives extreme temps Non visual ID Reads through frost On-board sensor Temperature sensing Reduced human error Productivity improvements 6

7 Primary Applications Sample tracking and identification Biopreservation Life sciences Research Pharmaceuticals Personalised Therapies 7

8 Strategy Market Primary Market Opportunity Global Biopreservation Market Greater than $2B in 2015 Non-cryogenic (-80C ) Cryogenic (-196C ) Total biobanking: 2B samples in storage 300M new samples per year Sources: Visual Fuse and MarketsandMarkets

9 Biobanking Today Segments Biosample tracking technology is not keeping up with the increasing value of biosamples Tissue Blood IVF Sperm/Eggs Biologics StemCell 9

10 Biobanking Today Needs Biopreservation Trends 300+ million biosamples per annum, 2+ billion in storage Icon here Icon here Icon here Icon here High volume processing Dual labelling Criticality of temperature on quality Increasing demand for Cryogenic storage 10

11 Strategy Adjacent Markets Other addressable markets Icon here Icon here Icon here Icon here Cold Chain Logistic Pharmaceuticals Cold Chain Logistics Food Industrial and Manufacturing Security & Defence Item level temperature tracking of pharmaceuticals through-out the cold chain cycle. Item level temperature tracking of frozen and temperature sensitive food stuffs through-out the cold chain cycle. High temperature tracking, structural health monitoring, tracking of tools and parts that are exposed to ionizing radiation or gamma radiation including sterilised medical devices, disposables and some food products. Anti counterfeiting fashion, food and high value commercial items. Cloning a bluechiip tag is extremely difficult. tracking of tools and parts that are exposed to ionizing radiation, security and defense. 11

12 Strategic Progress and Sales Pipeline 12

13 Technology Introduction Products Solutions for OEM Partners 13

14 NUMBER OF UNITS 1,800,000 2,500,000 3,000,000 3,700,000 15,000,000 7,500, M 300 M 300 M 2 B Strategy Market Opportunities High Value Target Markets Bluechiip Bluechiip Opportunity (USD) $20m+ $2.5M+ $30M+ $30M+ $200M+ opportunity ($US) $1.5B+ IVF PROTEIN REGENERATIVE MEDICINE CRYSTALLOGRAPHY Annual consumables (Chiips) OTHER CRYO AND TRANSPORT GENERAL BIOBANKING GENERAL BIOBANKING - NEXT GENERATION CHIPS Stored consumables OEM PIPELINE CLIENTS Agreement Dec 2015 Revenue Mar 2016 Displayed July 16 Target Launch 2017 Executed agreement Evaluation in progress Validation Customers Executed agreement Evaluation in progress Validation customers Evaluation agreements & developer kits in progress Developer kits sold with multiple vendors & validation customers R&D Development. High value over temperature sensors 14

15 Strategy Pipeline Progress 2016 Pipeline and Results Dramatic increase Engagement (Non- Disclosure Agreement) Sale of developer/trial kit, evaluation agreement Development & Supply agreement Demonstration in market Commercial product Bluechiip Inside Partner pipeline grown to over 30 opportunities Genea Biomedx OEM Supply Agreement Executed Planet Innovation - OEM Supply Agreement and Investment 2016: 9 Developer & Starter Kits sold with sales accelerating Mar : Autism CRC End user. Ongoing consumables Jun: US Cryogenics consumables manufacturer Australian researcher organisation Aug: Centre for Disease Control China (CDC China) Sep: US Auto ID and Data Capture Company Nov: Kit sale to CDC China 2 Kit sales to SIAD in EU biobank solution provider Kit sale to Denmark University OEM validator Dec: Kit sale to The Netherlands OEM Validation Validation End User 15

16 Strategy Partnering Genea Biomedx License & Supply Agreement Dec 2015 Genea Biomedx OEM Supply Agreement Executed Incorporate Bluechiips technology to Genea s range of Assisted Reproductive Technologies instruments Feb 2016 Successfully Completed concept due diligence July 2016 Demonstration in Market at (ESHRE) trade show Europe 2017 Pilot & Launch Commercial Product 16

17 Strategy Partnering Bluechiip IVF Transport Cooler Active ID and Temperature Recording in Liquid Nitrogen -196 o C 17

18 Strategy Partnering Planet Innovation OEM Partnership OEM Supply and Master Services Agreement Executed in September 16 Planet Innovation direct investment with a significant shareholding Actively pursuing partnerships to incorporate Bluechiip technology into Planet Innovation s Partners Products 18

19 Strategy Products Product Pipeline Chiips 19

20 Strategy Market feedback Market feedback. Independent Survey Sample Storage Quality & Identification Tracking Trends 2016 Largest markets US (47%) and Europe (27%) Freeze/Thaw cycles regarded as the main obstacle to sample quality Stored samples exposed to at least 1 significant temperature change per day Overtemperature regarded as the most valuable feature of all Estimated cost to replace a poor quality sample is USD With some samples well in excess of thousands of dollars. For MEMS ID fitted 2ml vials market potential is around USD $40M a year (2ml vials account for only a portion of the total vial storage market) Source: Independent market research report, Nov 2016, HTStec 20

21 Strategy Products Product Pipeline Readers Bluechiips Government co-funded projects with Melbourne and Swinburne Universities to adapt to multiple formats Over T C Overtemperature chip, 2nd stage funding awarded & Patent Application submitted 21

22 Strategy Products Bluechiip Blue Tray Active ID and Temperature Recording in Transit 22

23 Strategy Pipeline Progress Summary 1. Well protected and expanding differentiated IP portfolio 2. Large growing target market with very large adjacent market opportunities 3. Dramatically increasing partner pipeline with well advanced product development 4. Partner opportunity conversion with 2 executed licence and supply agreements 5. Initial repeat revenues with licence, service and product sales expected to grow in 2017 on partner s product launch 23

24 Need hi-res image Contact Andrew McLellan, Managing Director & CEO Tel: +61 (0) Mob: +61 (0)